J&J sales rose by 5.0% on a reported basis in Q1 2022 to US$23.4bn, with operational growth of 7.7%. Consumer Health sales fell by 1.5%, but grew 0.8% operationally. Excluding the net impact of acquisitions, divestitures and translational currency, adjusted CH operational sales increased by 1.6%. This was primarily driven by OTC products, with Tylenol and Motrin, upper respiratory products and Imodium major contributors.
P&G net sales rose by 7% in Q3 fiscal 2022 (Jan-Mar 2022) to US$19.4bn. Excluding the impact of foreign exchange, acquisitions and divestitures, organic sales grew by 10%, driven by a 3% rise in shipment volumes, 5% from increased pricing, and a 2% increase from positive geographic and product mix, with each category growing. Health Care – US$2.7bn, +13% – was once again P&G’s strongest division. Personal Health Care organic sales were up more than 30%, owing to a stronger cough / cold & flu season vs the prior year, as well as innovation in sleep and digestive wellness.
Nestlé sales rose by 5.4% in Q1 2022 to CHF22.2bn (US$23.4bn). Growth was broadly based across most geographies and categories. E-Commerce sales grew by 5.0%, building on 39.6% growth in Q1 2021. Nestlé Health Science, which earlier this month completed the acquisition of a majority stake in Orgain, a leader in plant-based nutrition, advanced by 55.8% to CHF1.4bn (US$1.5bn). Organic growth was 5.6%, building on two consecutive years of double-digit growth, with real internal growth of 4.3% and pricing +1.3%.
Nicholas Hall’s Touchpoints: Here at NHC we are in the final countdown for the Athens Conference, already postponed three times because of Covid. I’m looking forward so much to meeting delegates in the old-fashioned way, even if we are still required to wear masks and preserve some form of social distancing.
And we will have a lot to celebrate at the conference. Even though society is not quite ready for the New Normal – the pandemic is not yet over and almost certainly we will face a global recession in the months ahead – I sense a new optimism in the CHC industry. Some of our players are reporting positive and even spectacular results and the pulse of Licensing & Acquisition never slackens.
With less than two weeks to go until our 32nd European CHC Conference & CHC Training Academy Workshop, why not reserve your place now! Taking place in Athens on 4-6 May 2022, industry experts including speakers from Bayer, J&J, Menarini and Teva will explore how as an industry we can move forward with CHC Innovation. Contact elizabeth.bernos@NicholasHall.com to book your seat.